{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:17:21Z","timestamp":1791919041566,"version":"4.3.4"},"reference-count":148,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2022,10,6]],"date-time":"2022-10-06T00:00:00Z","timestamp":1665014400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecules"],"abstract":"<jats:p>Cancer is one of the top leading causes of death worldwide. It is a heterogenous disease characterized by unregulated cell proliferation and invasiveness of abnormal cells. For the treatment of cancer, natural products have been widely used as a source of therapeutic ingredients since ancient times. Although natural compounds and their derivatives have demonstrated strong antitumor activity in many types of cancer, their poor pharmacokinetic properties, low cell selectivity, limited bioavailability and restricted efficacy against drug-resistant cancer cells hinder their wide clinical application. Conjugation of natural products with other bioactive molecules has given rise to a new field in drug discovery resulting to the development of novel, bifunctional and more potent drugs for cancer therapy to overcome the current drawbacks. This review discusses multiple categories of such bifunctional conjugates and highlights recent trends and advances in the development of natural product hybrids. Among them, ADCs, PDCs, ApDCs, PROTACs and AUTOTACs represent emerging therapeutic agents against cancer.<\/jats:p>","DOI":"10.3390\/molecules27196632","type":"journal-article","created":{"date-parts":[[2022,10,9]],"date-time":"2022-10-09T23:31:43Z","timestamp":1665358303000},"page":"6632","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":49,"title":["Recent Advances in Natural Product-Based Hybrids as Anti-Cancer Agents"],"prefix":"10.3390","volume":"27","author":[{"given":"Eleni","family":"Sflakidou","sequence":"first","affiliation":[{"name":"Department of Chemistry, Aristotle University of Thessaloniki, University Campus, 54124 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3286-4781","authenticated-orcid":false,"given":"George","family":"Leonidis","sequence":"additional","affiliation":[{"name":"Department of Chemistry, Aristotle University of Thessaloniki, University Campus, 54124 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eirini","family":"Foroglou","sequence":"additional","affiliation":[{"name":"Department of Chemistry, Aristotle University of Thessaloniki, University Campus, 54124 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4102-9638","authenticated-orcid":false,"given":"Christos","family":"Siokatas","sequence":"additional","affiliation":[{"name":"Department of Chemistry, Aristotle University of Thessaloniki, University Campus, 54124 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6128-8277","authenticated-orcid":false,"given":"Vasiliki","family":"Sarli","sequence":"additional","affiliation":[{"name":"Department of Chemistry, Aristotle University of Thessaloniki, University Campus, 54124 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,10,6]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"3490","DOI":"10.1038\/s41467-018-05467-z","article-title":"Evaluating intrinsic and non-intrinsic cancer risk factors","volume":"9","author":"Wu","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"25","DOI":"10.2310\/7200.2006.029","article-title":"From Ancient Medicine to Modern Medicine: Ayurvedic Concepts of Health and Their Role in Inflammation and Cancer","volume":"5","author":"Garodia","year":"2007","journal-title":"J. Soc. Integr. Oncol."},{"key":"ref_3","first-page":"203","article-title":"Cancer Treatment by Greco-Arab and Islamic Herbal Medicine","volume":"3","author":"Zaid","year":"2010","journal-title":"Open Nutraceuticals J."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/s41573-020-00114-z","article-title":"Natural products in drug discovery: Advances and opportunities","volume":"20","author":"Atanasov","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1021\/acs.jmedchem.8b00686","article-title":"Two decades under the influence of the rule of five and the changing properties of approved oral drugs","volume":"62","author":"Shultz","year":"2019","journal-title":"J. Med. Chem."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1021\/acs.jafc.6b04815","article-title":"Physical and chemical stability of curcumin in aqueous solutions and emulsions: Impact of pH, temperature, and molecular environment","volume":"65","author":"Kharat","year":"2017","journal-title":"J. Agric. Food Chem."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1021\/np50100a001","article-title":"The taxol supply crisis. New NCI policies for handling the large-scale production of novel natural product anticancer and anti-HIV agents","volume":"56","author":"Cragg","year":"1993","journal-title":"J. Nat. Prod."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Colone, \u039c., Calcabrini, A., and Stringaro, A. (2020). Drug Delivery Systems of Natural Products in Oncology. Molecules, 25.","DOI":"10.3390\/molecules25194560"},{"key":"ref_9","first-page":"328","article-title":"A review on targeted drug delivery: Its entire focus on advanced therapeutics and diagnostics","volume":"2","author":"Rani","year":"2014","journal-title":"Sch. J. Appl. Med. Sci."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"12128","DOI":"10.1073\/pnas.0805374105","article-title":"Overcoming multidrug resistance of small-molecule therapeutics through conjugation with releasable octaarginine transporters","volume":"105","author":"Dubikovskaya","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.tips.2005.02.007","article-title":"The efficiency of multi-target drugs: The network approach might help drug design","volume":"26","author":"Csermely","year":"2005","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"711","DOI":"10.2174\/1389450116666150309115922","article-title":"Heterocyclic scaffolds: Centrality in the anticancer drug development","volume":"16","author":"Ali","year":"2015","journal-title":"Curr. Drug Targets"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/s41419-019-1611-4","article-title":"Combination of 5-fluorouracil and thymoquinone targets stem cell gene signature in colorectal cancer cells","volume":"10","author":"Ndreshkjana","year":"2019","journal-title":"Cell Death Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.tcb.2005.07.004","article-title":"Cancer stem cells: Lessons from leukemia","volume":"15","author":"Wang","year":"2005","journal-title":"Trends Cell Biol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"7762","DOI":"10.1021\/acs.chemrev.7b00020","article-title":"Chalcone: A Privileged Structure in Medicinal Chemistry","volume":"117","author":"Zhuang","year":"2017","journal-title":"Chem. Rev."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Ramirez-Tagle, R., Escobar, C., Romero, V., Montorfano, I., Armis\u00e9n, R., Borgna, V., Jeldes, E., Pizarro, L., Simon, F., and Echeverria, C. (2016). Chalcone-induced apoptosis through caspase-dependent intrinsic pathways in human hepatocellular carcinoma cells. Int. J. Mol. Sci., 17.","DOI":"10.3390\/ijms17020260"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1007\/s10637-019-00737-z","article-title":"An orally antitumor chalcone hybrid inhibited HepG2 cells growth and migration as the tubulin binding agent","volume":"37","author":"Wang","year":"2019","journal-title":"Investig. New Drugs"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1039\/C5MD00219B","article-title":"Synthesis and anti-cancer screening of novel heterocyclic-(2H)-1,2,3-triazoles as potential anti-cancer agents","volume":"6","author":"Penthala","year":"2015","journal-title":"Med. Chem. Comm."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"3820","DOI":"10.1016\/j.ejmech.2011.05.050","article-title":"Synthesis and anticancer activity of chalcone-pyrrolobenzodiazepine conjugates linked via 1,2,3-triazole ring side-armed with alkane spacers","volume":"46","author":"Kamal","year":"2011","journal-title":"Eur. J. Med. Chem."},{"key":"ref_20","first-page":"2429","article-title":"Novel coumarin compounds potentiate the effect of cisplatin on lung cancer cells by enhancing pro-apoptotic gene expressions, G2\/M cell arrest, oxidative and antiangiogenic effects","volume":"22","year":"2022","journal-title":"Anticancer Agents Med. Chem."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/s12276-020-0384-2","article-title":"ROS in cancer therapy: The bright side of the moon","volume":"52","author":"Perillo","year":"2020","journal-title":"Exp. Mol. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.4103\/1673-5374.162686","article-title":"Curcumin and Apigenin\u2014Novel and promising therapeutics against chronic neuroinflammation in Alzheimer\u2019s disease","volume":"10","author":"Venigalla","year":"2015","journal-title":"Neural Regen. Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"12089","DOI":"10.1021\/acs.jmedchem.1c00735","article-title":"Discovery of Novel Apigenin\u2212Piperazine Hybrids as Potent and Selective Poly (ADP-Ribose) Polymerase-1 (PARP-1) Inhibitors for the Treatment of Cancer","volume":"64","author":"Long","year":"2021","journal-title":"J. Med. Chem."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"4920","DOI":"10.1016\/j.arabjc.2016.10.009","article-title":"Comprehensive review on current developments of quinoline-based anticancer agents","volume":"12","author":"Jain","year":"2019","journal-title":"Arab. J. Chem."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1517\/13543776.2014.902052","article-title":"Acridine and its derivatives: A patent review (2009\u20132013)","volume":"24","author":"Zhang","year":"2014","journal-title":"Expert. Opin. Ther. Pat."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Lisboa, T., Silva, D., Duarte, S., Ferreira, R., Andrade, C., Lopes, A.L., Ribeiro, J., Farias, D., Moura, R., and Reis, M. (2020). Toxicity and Antitumor Activity of a Thiophene\u2013Acridine Hybrid. Molecules, 25.","DOI":"10.3390\/molecules25010064"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1182\/blood-2019-131520","article-title":"The VITAL Trial: Phase II Trial of Vosaroxin and Infusional Cytarabine for Frontline Treatment of acute Myeloid Leukemia","volume":"134","author":"Strickland","year":"2019","journal-title":"Blood"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1158\/1078-0432.CCR-06-2328","article-title":"Approval summary: Sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma","volume":"13","author":"Goodman","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"ref_29","unstructured":"National Institute for Health and Care Excellence (2022, August 26). Nintedanib for Treating Idiopathic Pulmonary Fibrosis, Available online: https:\/\/www.nice.org.uk\/guidance\/ta379."},{"key":"ref_30","first-page":"10187","article-title":"Navigating the Synthesis of Quinoline Hybrid Molecules as Promising Anticancer Agents","volume":"5","author":"Panda","year":"2020","journal-title":"Chem. Sel."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"111587","DOI":"10.1016\/j.ejmech.2019.111587","article-title":"Coumarin-containing hybrids and their anticancer activities","volume":"181","author":"Zhang","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"3477","DOI":"10.1016\/j.bmc.2019.06.033","article-title":"Rational approaches, design strategies, structure activity relationship and mechanistic insights for therapeutic coumarin hybrids","volume":"27","author":"Singh","year":"2019","journal-title":"Bioorg. Med. Chem."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"112359","DOI":"10.1016\/j.ejmech.2020.112359","article-title":"Current scenario of indole derivatives with potential anti-drugresistant cancer activity","volume":"200","author":"Jia","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ejmech.2019.111691","article-title":"Indole: A privileged scaffold for the design of anti-cancer agents","volume":"183","author":"Wan","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0304-3835(02)00322-1","article-title":"Induction and Superinduction of Growth Arrest and DNA Damage Gene 45 (Gadd45) Alpha and Beta Messenger Rnas by Histone Deacetylase Inhibitors Trichostatin a (Tsa) and Butyrate in Sw620 Human Colon Carcinoma Cells","volume":"188","author":"Chen","year":"2002","journal-title":"Cancer Lett."},{"key":"ref_36","first-page":"679","article-title":"Fr901228, a Novel Histone Deacetylase Inhibitor, Induces Cell Cycle Arrest and Subsequent Apoptosis in Refractory Human Pancreatic Cancer Cells","volume":"24","author":"Sato","year":"2004","journal-title":"Int. J. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1002\/ijc.10699","article-title":"Histone, Deacetylase Inhibitor Trichostatin a Induces Cell-Cycle Arrest\/Apoptosis and Hepatocyte Differentiation in Human Hepatoma Cells","volume":"103","author":"Yamashita","year":"2003","journal-title":"Int. J. Cancer"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.ccell.2016.08.001","article-title":"Feedback Activation of Leukemia Inhibitory Factor Receptor Limits Response to Histone Deacetylase Inhibitors in Breast Cancer","volume":"30","author":"Zeng","year":"2016","journal-title":"Cancer Cell"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"7468","DOI":"10.1021\/acs.jmedchem.1c00136","article-title":"Discovery of STAT3 and Histone Deacetylase (HDAC) Dual-Pathway Inhibitors for the Treatment of Solid Cancer","volume":"64","author":"Ren","year":"2021","journal-title":"J. Med. Chem."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/nrc1716","article-title":"HSP90 and the chaperoning of cancer","volume":"5","author":"Whitesell","year":"2005","journal-title":"Nat. Rev. Cancer"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1021\/cb600224w","article-title":"Tumor selectivity of Hsp90 inhibitors: The explanation remains elusive","volume":"1","author":"Chiosis","year":"2006","journal-title":"ACS Chem. Biol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.drudis.2007.10.007","article-title":"Development and application of Hsp90 inhibitors","volume":"13","author":"Solit","year":"2008","journal-title":"Drug Discov. Today"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"114013","DOI":"10.1016\/j.ejmech.2021.114013","article-title":"Discovery of BP3 as an efficacious proteolysis targeting chimera (PROTAC) degrader of HSP90 for treating breast cancer","volume":"228","author":"Liu","year":"2002","journal-title":"Eur. J. Med. Chem."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/BF00689048","article-title":"Preclinical pharmacologic evaluation of geldanamycin as an antitumor agent","volume":"36","author":"Supko","year":"1995","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"114582","DOI":"10.1016\/j.ejmech.2022.114582","article-title":"Design, synthesis, and biological evaluation of bifunctional inhibitors against Hsp90-HDAC6 interplay","volume":"240","author":"Chae","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1002\/1878-0261.12054","article-title":"Histone deacetylase activity mediates acquired resistance towards structurally diverse HSP90 inhibitors","volume":"11","author":"Chai","year":"2017","journal-title":"Mol. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/nrc3237","article-title":"Combining immunotherapy and targeted therapies in cancer treatment","volume":"12","author":"Vanneman","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.it.2016.04.010","article-title":"Targeted therapy and checkpoint immunotherapy combinations for the treatment of cancer","volume":"37","author":"Hughes","year":"2016","journal-title":"Trends Immunol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"6752","DOI":"10.1002\/anie.201402879","article-title":"Immunochemotherapeutic platinum (IV) prodrugs of cisplatin as multimodal anticancer agents","volume":"53","author":"Wong","year":"2014","journal-title":"Angew. Chem. Int. Ed."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1021\/acs.jmedchem.9b01386","article-title":"Bifunctional Naphthoquinone Aromatic Amide-Oxime Derivatives Exert Combined Immunotherapeutic and Antitumor Effects through Simultaneous Targeting of Indoleamine-2,3-dioxygenase and Signal Transducer and Activator of Transcription 3","volume":"63","author":"Huang","year":"2020","journal-title":"J. Med. Chem."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"7963","DOI":"10.1021\/acs.jmedchem.1c00100","article-title":"Recent Progress on Tubulin Inhibitors with Dual Targeting Capabilities for Cancer Therapy","volume":"64","author":"Shuai","year":"2021","journal-title":"J. Med. Chem."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Szumilak, M., Wiktorowska-Owczarek, A., and Stanczak, A. (2021). Hybrid Drugs\u2014A Strategy for Overcoming Anticancer Drug Resistance?. Molecules, 26.","DOI":"10.3390\/molecules26092601"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.fshw.2021.11.001","article-title":"Potential Application of Proteolysis Targeting Chimera (PROTAC) Modification Technology in Natural Products for Their Targeted Protein Degradation","volume":"11","author":"Yang","year":"2022","journal-title":"Food Sci. Hum. Wellness"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"114056","DOI":"10.1016\/j.ejmech.2021.114056","article-title":"Transcriptional Cyclin-Dependent Kinases: Potential Drug Targets in Cancer Therapy","volume":"229","author":"Liu","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.bioorg.2018.08.028","article-title":"Discovery of Wogonin-Based PROTACs against CDK9 and Capable of Achieving Antitumor Activity","volume":"81","author":"Bian","year":"2018","journal-title":"Bioorg. Chem."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"104453","DOI":"10.1016\/j.bioorg.2020.104453","article-title":"Targeted Degradation of CD147 Proteins in Melanoma","volume":"105","author":"Zhou","year":"2020","journal-title":"Bioorg. Chem."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"104901","DOI":"10.1016\/j.bioorg.2021.104901","article-title":"Design and Linkage Optimization of Ursane-Thalidomide-Based PROTACs and Identification of Their Targeted-Degradation Properties to MDM2 Protein","volume":"111","author":"Qi","year":"2021","journal-title":"Bioorg. Chem."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"112608","DOI":"10.1016\/j.jep.2020.112608","article-title":"A Review of Traditional Uses, Phytochemistry and Pharmacology of the Genus Indigofera","volume":"253","author":"Gerometta","year":"2020","journal-title":"J. Ethnopharmacol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"2746","DOI":"10.1021\/acschembio.1c00681","article-title":"Attenuation of NLRP3 Inflammasome Activation by Indirubin-Derived PROTAC Targeting HDAC6","volume":"16","author":"Cao","year":"2021","journal-title":"ACS Chem. Biol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1021\/np50104a008","article-title":"Anti-AIDS Agents, 11. Betulinic Acid and Platanic Acid as Anti-HIV Principles from Syzigium Claviflorum, and the Anti-HIV Activity of Structurally Related Triterpenoids","volume":"57","author":"Fujioka","year":"1997","journal-title":"J. Nat. Prod."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1093\/jb\/mvac021","article-title":"Hybrid Molecule between Platanic Acid and LCL-161 as a Yes-Associated Protein Degrader","volume":"171","author":"Nakano","year":"2022","journal-title":"J. Biochem."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/s41589-019-0304-8","article-title":"Harnessing the Anti-Cancer Natural Product Nimbolide for Targeted Protein Degradation","volume":"15","author":"Spradlin","year":"2019","journal-title":"Nat. Chem. Biol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1021\/acschembio.0c00348","article-title":"Nimbolide-Based Kinase Degrader Preferentially Degrades Oncogenic BCR-ABL","volume":"15","author":"Tong","year":"2020","journal-title":"ACS Chem. Biol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"e202100270","DOI":"10.1002\/cbic.202100270","article-title":"Recent Developments in PROTAC-Mediated Protein Degradation: From Bench to Clinic","volume":"23","author":"Hu","year":"2022","journal-title":"ChemBioChem"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"85","DOI":"10.3389\/fonc.2017.00085","article-title":"The KEAP1\u2013NRF2 System in Cancer","volume":"7","author":"Taguchi","year":"2017","journal-title":"Front. Oncol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"15543","DOI":"10.1038\/s41598-020-72491-9","article-title":"Bardoxolone Conjugation Enables Targeted Protein Degradation of BRD4","volume":"10","author":"Tong","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"12780","DOI":"10.1111\/acel.12780","article-title":"Oxidation Resistance 1 Is a Novel Senolytic Target","volume":"17","author":"Zhang","year":"2018","journal-title":"Aging Cell"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1016\/j.cclet.2020.08.049","article-title":"Radiosensitization of Human Pancreatic Cancer by Piperlongumine Analogues","volume":"32","author":"Ma","year":"2020","journal-title":"Chin. Chem. Lett."},{"key":"ref_69","unstructured":"Pei, J., Xiao, Y., Liu, X., Hu, W., Sobh, A., Yuan, Y., Zhou, S., Hua, N., Mackintosh, S.G., and Zhang, X. (2022). Identification of Piperlongumine (PL) as a New E3 Ligase Ligand to Induce Targeted Protein Degradation. bioRxiv."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/nrm4024","article-title":"Autophagy at the crossroads of catabolism and anabolism","volume":"16","author":"Kaur","year":"2015","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.devcel.2017.02.016","article-title":"Cleaning house: Selective autophagy of organelles","volume":"41","author":"Anding","year":"2017","journal-title":"Dev. Cell"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/s41467-022-28520-4","article-title":"The AUTOTAC Chemical Biology Platform for Targeted Protein Degradation via the Autophagy-Lysosome System","volume":"13","author":"Ji","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.4155\/fmc-2018-0174","article-title":"Cancer-targeted delivery systems based on peptides","volume":"10","author":"Chatzisideri","year":"2018","journal-title":"Future Med. Chem."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.ab.2004.12.026","article-title":"Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay","volume":"338","author":"Parker","year":"2005","journal-title":"Anal. Biochem."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"414","DOI":"10.18632\/oncotarget.519","article-title":"Folate receptor alpha expression in lung cancer: Diagnostic and prognostic significance","volume":"3","author":"Yu","year":"2012","journal-title":"Oncotarget"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/s41571-020-0339-5","article-title":"Exploiting the folate receptor \u03b1 in oncology","volume":"17","author":"Scaranti","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"8943","DOI":"10.1038\/s41598-018-27320-5","article-title":"Pre-clinical evaluation of EC1456, a folate-tubulysin anti-cancer therapeutic","volume":"8","author":"Reddy","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"8224","DOI":"10.1021\/jm500101h","article-title":"Targeting the androgen receptor with steroid conjugates","volume":"57","author":"Levine","year":"2014","journal-title":"J. Med. Chem."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1517\/17460441.2016.1135125","article-title":"An overview of molecular hybrids in drug discovery","volume":"11","year":"2016","journal-title":"Expert Opin. Drug Discov."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2010.09.008","article-title":"Steroid hormone receptors in cancer development: A target for cancer therapeutics","volume":"300","author":"Ahmad","year":"2011","journal-title":"Cancer Lett."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"4628","DOI":"10.1016\/j.bmcl.2015.08.041","article-title":"Discovery of novel isatin\u2013dehydroepiandrosterone conjugates as potential anticancer agents","volume":"25","author":"Ke","year":"2015","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1080\/14756366.2019.1659790","article-title":"Synthesis and bioevaluation of novel steroidal isatin conjugates derived from epiandrosterone\/androsterone","volume":"34","author":"Ke","year":"2019","journal-title":"J. Enzyme. Inhib. Med. Chem."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.steroids.2018.06.011","article-title":"Conjugates of 17-substituted testosterone and epitestosterone with pyropheophorbide a differing in the length of linkers","volume":"138","author":"Zolottsev","year":"2018","journal-title":"Steroids"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.2147\/DDDT.S168588","article-title":"Doxorubicin-conjugated dexamethasone induced MCF-7 apoptosis without entering the nucleus and able to overcome MDR-1-induced resistance","volume":"12","author":"Chaikomon","year":"2018","journal-title":"Drug Des. Devel. Ther."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jfda.2016.11.004","article-title":"Food macromolecule based nanodelivery systems for enhancing the bioavailability of polyphenols","volume":"25","author":"Hu","year":"2017","journal-title":"J. Food Drug Anal."},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Zheng, B., and McClements, D.J. (2020). Formulation of More Efficacious Curcumin Delivery Systems Using Colloid Science: Enhanced Solubility, Stability, and Bioavailability. Molecules, 25.","DOI":"10.3390\/molecules25122791"},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Micale, \u039d., Molonia, M.S., Citarella, A., Cimino, F., Saija, A., Cristani, M., and Speciale, A. (2021). Natural Product-Based Hybrids as Potential Candidates for the Treatment of Cancer: Focus on Curcumin and Resveratrol. Molecules, 26.","DOI":"10.3390\/molecules26154665"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"6452","DOI":"10.3390\/molecules15096452","article-title":"Honokiol and magnolol as multifunctional antioxidative molecules for dermatologic disorders","volume":"15","author":"Shen","year":"2010","journal-title":"Molecules"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"141","DOI":"10.3390\/medicines2030141","article-title":"Sulforaphane (SFN): An isothiocyanate in a cancer chemoprevention paradigm","volume":"2","author":"Ullah","year":"2015","journal-title":"Medicines"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"112441","DOI":"10.1016\/j.ejmech.2020.112441","article-title":"CT1-3, a novel magnolol-sulforaphane hybrid suppresses tumorigenesis through inducing mitochondria-mediated apoptosis and inhibiting epithelial mesenchymal transition","volume":"199","author":"Tao","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"ref_91","first-page":"247597","article-title":"Antitumor activity of artemisinin and its derivatives: From a well-known antimalarial agent to a potential anticancer drug","volume":"2012","author":"Wei","year":"2012","journal-title":"J. Biomed. Biotechnol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"93","DOI":"10.4103\/2141-9248.153609","article-title":"Anticancer Effect of antimalarial artemisinin compounds","volume":"5","author":"Das","year":"2015","journal-title":"Ann. Med. Health Sci. Res."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.bcp.2017.03.019","article-title":"Cancer combination therapies with artemisinin-type drugs","volume":"139","author":"Efferth","year":"2017","journal-title":"Biochem. Pharmacol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.pharmthera.2013.12.001","article-title":"Artemisinins: Pharmacological actions beyond anti-malarial","volume":"142","author":"Ho","year":"2014","journal-title":"Pharmacol. Ther."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1248\/cpb.59.1471","article-title":"Discovery of artemisinin-glycolipid hybrids as anti-oral cancer agents","volume":"59","author":"Ricci","year":"2011","journal-title":"Chem. Pharm. Bull."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1159\/000493449","article-title":"Artemisinin-Daumone Hybrid Inhibits Cancer Cell-Mediated Osteolysis by Targeting Cancer Cells and Osteoclasts","volume":"49","author":"Ma","year":"2018","journal-title":"Cell Physiol. Biochem."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s12985-015-0264-x","article-title":"Formononetin inhibits enterovirus 71 replication by regulating COX-2\/PGE2 expression","volume":"12","author":"Wang","year":"2015","journal-title":"Virol. J."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"16815","DOI":"10.1038\/srep16815","article-title":"Formononetin promotes angiogenesis through the estrogen receptor alpha enhanced ROCK pathway","volume":"5","author":"Li","year":"2015","journal-title":"Sci. Rep."},{"key":"ref_99","first-page":"3048532","article-title":"Formononetin administration ameliorates dextran sulfate sodium-induced acute colitis by inhibiting NLRP3 Inflammasome signaling pathway","volume":"2018","author":"Wu","year":"2018","journal-title":"Mediat. Inflamm."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1007\/s10637-019-00767-7","article-title":"Discovery and anticancer evaluation of a formononetin derivative against gastric cancer SGC7901 cells","volume":"37","author":"Yao","year":"2019","journal-title":"Investig. New Drugs"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.ijantimicag.2018.06.019","article-title":"\u03b2-Carboline derivatives as novel antivirals for herpes simplex viruses","volume":"52","author":"Gonzalez","year":"2018","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.ejmech.2017.12.055","article-title":"Synthesis of podophyllotoxin linked \u03b2-car- boline congeners as potential anticancer agents and DNA topoisomerase II inhibitors","volume":"144","author":"Sathish","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1002\/cmdc.201800402","article-title":"Design and synthesis of DNA-interactive \u03b2-carboline-oxindole hybrids as cytotoxic and apoptosis-inducing agents","volume":"13","author":"Tokala","year":"2018","journal-title":"Chem. Med. Chem."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"103612","DOI":"10.1016\/j.bioorg.2020.103612","article-title":"Molecular hybrid design, synthesis, in vitro and in vivo anticancer evaluation, and mechanism of action of N-acylhydrazone linked, heterobivalent \u03b2-carboline","volume":"96","author":"Guo","year":"2020","journal-title":"Bioorg. Chem."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ejmech.2018.03.057","article-title":"Success stories of natural product-based hybrid molecules for multi-factorial diseases","volume":"151","author":"Choudhary","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.pharmthera.2017.03.004","article-title":"Antibodies and associates: Partners in targeted drug delivery","volume":"177","author":"Kennedy","year":"2017","journal-title":"Pharmacol. Ther."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s13238-016-0323-0","article-title":"Antibody-drug conjugates: Recent advances in conjugation and linker chemistries","volume":"9","author":"Tsuchikama","year":"2018","journal-title":"Protein Cell"},{"key":"ref_108","unstructured":"Sharma, V. (2022, August 27). CPhI Annual Report 2018: ADCs Growth Driven by Lack of In-House Facilities, Oncology and Integrated CDMOs|Pharmaceutical Outsourcing\u2014The Journal of Pharmaceutical & Biopharmaceutical Contract Services (pharmoutsourcing.com). Available online: https:\/\/www.pharmoutsourcing.com\/Featured-Articles\/354437-CPhI-Annual-Report-2018-ADCs-Growth-Driven-by-Lack-of-In-House-Facilities-Oncology-and-Integrated-CDMOs\/."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1016\/j.annonc.2020.06.020","article-title":"Trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer and brain metastases: Exploratory final analysis of cohort 1 from KAMILLA, a single-arm phase IIIb clinical trial","volume":"31","author":"Montemurro","year":"2020","journal-title":"Ann. Oncol."},{"key":"ref_110","doi-asserted-by":"crossref","unstructured":"Hafeez, U., Parakh, S., Gan, H.K., and Scott, A.M. (2020). Antibody\u2013Drug Conjugates for Cancer Therapy. Molecules, 25.","DOI":"10.3390\/molecules25204764"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1200\/JCO.2009.26.2071","article-title":"Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer","volume":"28","author":"Krop","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/S1470-2045(17)30313-3","article-title":"Trastuzumab emtansine versus treatment of physician\u2019s choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): Final overall survival results from a randomised open-label phase 3 trial","volume":"18","author":"Krop","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1200\/JCO.2011.38.0402","article-title":"Shustov ABrentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study","volume":"30","author":"Pro","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"e387","DOI":"10.1016\/S2352-3026(17)30103-5","article-title":"Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukemia: Results from the open-label, randomised, phase 3 INO-VATE study","volume":"4","author":"Kantarjian","year":"2017","journal-title":"Lancet Haematol."},{"key":"ref_115","first-page":"1490","article-title":"Approval summary: Gemtuzumab ozogamicin in relapsed acute myeloid leukemia","volume":"7","author":"Bross","year":"2001","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1200\/JCO.19.00172","article-title":"Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma","volume":"38","author":"Sehn","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJMoa2115304","article-title":"Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma","volume":"386","author":"Tilly","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1056\/NEJMoa1914510","article-title":"Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer","volume":"382","author":"Modi","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1200\/JCO.19.01140","article-title":"Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1\/Programmed Death Ligand 1 Therapy","volume":"37","author":"Rosenberg","year":"2019","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1056\/NEJMoa1814213","article-title":"Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer","volume":"380","author":"Bardia","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1111\/j.1365-2141.2012.09241.x","article-title":"Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival","volume":"158","author":"Sanchez","year":"2012","journal-title":"Br. J. Haematol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S1470-2045(19)30788-0","article-title":"Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): A two-arm, randomised, open-label, phase 2 study","volume":"21","author":"Lonial","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_123","first-page":"12929","article-title":"Conjugating MMAE to a novel antiHER2 antibody for selective targeted delivery","volume":"24","author":"Li","year":"2020","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1158\/1078-0432.CCR-20-2488","article-title":"Open-label, multicenter, phase II study of RC48-ADC, a HER2-targeting antibody-drug conjugate, in patients with locally advanced or metastatic urothelial carcinoma","volume":"27","author":"Sheng","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"188549","DOI":"10.1016\/j.bbcan.2021.188549","article-title":"HER2-targeted therapies in gastric cancer","volume":"1876","author":"Zhu","year":"2021","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1007\/s10120-021-01168-7","article-title":"Phase I study of the recombinant humanized anti-HER2 monoclonal antibody-MMAE conjugate RC48-ADC in patients with HER2-positive advanced solid tumors","volume":"24","author":"Xu","year":"2021","journal-title":"Gastric Cancer"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1080\/10717544.2022.2069883","article-title":"Disitamab vedotin: A novel antibody-drug conjugates for cancer therapy","volume":"29","author":"Shi","year":"2022","journal-title":"Drug Deliv."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"126782","DOI":"10.1016\/j.bmcl.2019.126782","article-title":"Design, synthesis and biological evaluation of phenol-linked uncialamycin antibody-drug conjugates","volume":"30","author":"Poudel","year":"2020","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.addr.2016.06.015","article-title":"Peptide\u2013drug conjugates as effective prodrug strategies for targeted delivery","volume":"110","author":"Wang","year":"2017","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_130","first-page":"1807","article-title":"Expression of the prostate-specific membrane antigen","volume":"54","author":"Israeli","year":"1994","journal-title":"Cancer Res."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1038\/bjc.2016.72","article-title":"Mipsagargin, a novel thapsigargin-based PSMA-activated prodrug: Results of a first-in-man phase I clinical trial in patients with refractory, advanced or metastatic solid tumors","volume":"114","author":"Mahalingam","year":"2016","journal-title":"Br. J. Cancer"},{"key":"ref_132","doi-asserted-by":"crossref","unstructured":"Mahalingam, D., Peguero, J., Cen, P., Arora, S., Sarantopoulos, J., Rowe, J., Allgood, V., Tubb, B., and Campos, L. (2019). A Phase II, Multicenter, Single-Arm Study of Mipsagargin (G-202) as a Second-Line Therapy Following Sorafenib for Adult Patients with Progressive Advanced Hepatocellular Carcinoma. Cancers, 11.","DOI":"10.3390\/cancers11060833"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1158\/1535-7163.MCT-19-0022","article-title":"Targeting the Somatostatin Receptor 2 with the Miniaturized Drug Conjugate, PEN-221: A Potent and Novel Therapeutic for the Treatment of Small Cell Lung Cancer","volume":"18","author":"Whalen","year":"2019","journal-title":"Mol. Cancer Ther."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1158\/1535-7163.MCT-19-1092","article-title":"MMAE Delivery Using the Bicycle Toxin Conjugate BT5528","volume":"19","author":"Bennett","year":"2020","journal-title":"Mol. Cancer Ther."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1158\/1078-0432.CCR-05-1505","article-title":"Expression of EphA2 and Ephrin A-1 in carcinoma of the urinary bladder","volume":"12","author":"Abraham","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"101","DOI":"10.4155\/bio-2020-0256","article-title":"Development of a LC\u2013MS\/MS method for the quantification of toxic payload DM1 cleaved from BT1718 in a Phase I study","volume":"13","author":"Gowland","year":"2021","journal-title":"Bioanalysis"},{"key":"ref_137","unstructured":"(2022, August 29). Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer (ZoptEC): Identifier: NCT01767155, Available online: https:\/\/clinicaltrials.gov."},{"key":"ref_138","unstructured":"ANGLeD (2022, August 29). ANG1005 in Leptomeningeal Disease from Breast Cancer (ANGLeD): Identifier: NCT03613181, Available online: https:\/\/clinicaltrials.gov."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/nrd.2016.199","article-title":"Aptamers as targeted therapeutics: Current potential and challenges","volume":"16","author":"Zhou","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"4761","DOI":"10.1073\/pnas.1717705115","article-title":"Tunable cytotoxic aptamer\u2013drug conjugates for the treatment of prostate cancer","volume":"115","author":"Gray","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_141","doi-asserted-by":"crossref","unstructured":"Jeong, H.Y., Kim, H., Lee, M., Hong, J., Lee, J.H., and Kim, J. (2020). Development of HER2-Specific Aptamer-Drug Conjugate for Breast Cancer Therapy. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21249764"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.1021\/jacs.9b10510","article-title":"Molecularly Engineer Triptolide with Aptamers for High Specifici-ty and Cytotoxicity for Triple-Negative Breast Cancer","volume":"142","author":"He","year":"2020","journal-title":"J. Am. Chem. Soc."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s40824-021-00244-4","article-title":"Design and clinical developments of aptamer-drug conjugates for targeted cancer therapy","volume":"25","author":"Kim","year":"2021","journal-title":"Biomater. Res."},{"key":"ref_144","unstructured":"Shipra, Y. (2021). Potential of Metal Complexes for the Treatment of Cancer: Current Update and Future Prospective. Chemistry of Biologically Potent Natural Products and Synthetic Compounds, Scrivener Publishing LLC."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.poly.2017.04.005","article-title":"Ruthenium(II)\/Triphenylphosphine Complexes: An Effective Way to Improve the Cytotoxicity of Lapachol","volume":"130","author":"Oliveira","year":"2017","journal-title":"Polyhedron"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jorganchem.2017.02.005","article-title":"Approach to Ferrocenyl-Podophyllotoxin Analogs and Their Evaluation as Anti-Tumor Agents","volume":"839","author":"Beauperin","year":"2017","journal-title":"J. Organomet. Chem."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/j.biotechadv.2015.08.001","article-title":"Discovery and resupply of pharmacologically active plant-derived natural products: A review","volume":"33","author":"Atanasov","year":"2015","journal-title":"Biotechnol. Adv."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/nrd4510","article-title":"The re-emergence of natural products for drug discovery in the genomics era","volume":"14","author":"Harvey","year":"2015","journal-title":"Nat. Rev. Drug Discov."}],"container-title":["Molecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1420-3049\/27\/19\/6632\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:47:14Z","timestamp":1760143634000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1420-3049\/27\/19\/6632"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,6]]},"references-count":148,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2022,10]]}},"alternative-id":["molecules27196632"],"URL":"https:\/\/doi.org\/10.3390\/molecules27196632","relation":{},"ISSN":["1420-3049"],"issn-type":[{"value":"1420-3049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,6]]}}}